Table 1.
Baseline Characteristics of the CPB Group and the ESBL-PE Group
| Characteristic | CPB Group (n=50) | ESBL-PE Group (n=572) | P Value | ||
|---|---|---|---|---|---|
| No. or Median | % or IQR | No. or Median | % or IQR | ||
| Demographics and clinical data | |||||
| Sex, female | 24 | 48.0 | 277 | 48.4 | .954 |
| Age, median y | 63 | 53–75 | 70 | 56–81 | .090 |
| Admission from | <.001 | ||||
| Home | 25 | 50.0 | 401 | 70.1 | |
| Nursing home | 2 | 4.0 | 69 | 12.1 | |
| Other acute healthcare facility | 23 | 46.0 | 99 | 17.3 | |
| Unknown | 0 | 3 | 0.5 | ||
| Ward | <.001 | ||||
| Medical | 17 | 34.0 | 332 | 58.0 | |
| Surgery | 28 | 56.0 | 188 | 32.9 | |
| Other | 5 | 10.0 | 52 | 9.1 | |
| Stay in ICU within the index hospitalization | 22 | 44.0 | 144 | 25.2 | .004 |
| Length of hospital stay, d | 22 | 9–42 | 13 | 7–23 | .002 |
| Death | 9 | 18.0 | 32 | 5.6 | .001 |
| History of hospitalization a | 42 | 84.0 | 396 | 69.2 | .028 |
| History of ICU stay a | 10 | 20.0 | 87 | 15.2 | .371 |
| Travel history a | 31 | 62.0 | 89 | 15.6 | <.001 |
| Hospitalization abroad a | 30 | 60.0 | 35 | 6.12 | <.001 |
| Charlson comorbidity index | 1 | 1–2 | 2 | 0–3 | .692 |
| Open wounds | 9 | 18.0 | 66 | 11.5 | .178 |
| Recent surgery a | 27 | 54.0 | 160 | 28.0 | <.001 |
| Urinary catheterization b | 21 | 42.0 | 173 | 30.2 | .085 |
| Indwelling vascular hardware c | 4 | 8.0 | 22 | 3.9 | .159 |
| Dialysis | 1 | 2.0 | 10 | 1.8 | .897 |
| Solid-organ transplantation | 0 | 0 | 28 | 4.9 | .109 |
| Allogeneic stem-cell transplantation | 1 | 2.0 | 16 | 2.8 | .740 |
| History of colonization with CPB or ESBL-PE a,d | 12 | 24.0 | 237 | 41.4 | .016 |
| Recent antibiotic therapy e | 39 | 78.0 | 279 | 48.8 | <.001 |
| Duration of antibiotic therapy, d | 9.5 | 4-23 | 13 | 6-32 | .193 |
| Immunosuppressive therapy a | 10 | 20.0 | 154 | 26.9 | .287 |
| Proton-pump inhibitor e | 22 | 44.0 | 317 | 55.4 | .120 |
Note. CPB, carbapenemase-producing bacteria; ESBL-PE, extended-spectrum β-lactamase–producing Enterobacterales; IQR, interquartile range; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci. Bold indicates statistical significance.
a
Within the previous 12 mo.
b
Within 30 d prior to CPB detection.
c
To be in place for at least 7 d prior to CPB detection.
d
refers to ESBL-PE and/or CPB in the CPB group and to only ESBL-PE in the ESBL-PE group.
e
Within 3 mo prior to CPB detection.